Diffuse Midline Glioma, H3 K27M-Mutant

Diseases /

Diffuse Midline Glioma, H3 K27M-Mutant

Back to Diseases List

Associated Genetic Biomarkers

EGFR
EGFR A289T
EGFR A864V
EGFR Codon 719 Missense
EGFR E709K
EGFR E746_A750del
EGFR Exon 20 Insertion
EGFR Exons 2-7 Skipping
EGFR G598V
EGFR L858R
EGFR L861Q
EGFR P596L
EGFR R108K
EGFR R222C
EGFR R831C
EGFR R831H
EGFR S768I
EGFR T790M
EGFR V742I
EGFR V769M

EGFR V774M
ERBB2
ERBB2 T798I
ERBB2 T798M
H3F3A
H3F3A K28M
HIST1H3C
HIST1H3C K28M
HLA-A*02:01 Positive
RB1

RB1 Expression
RB1 Loss
RB1 Mutation

Overview

NCI Definition: A childhood diffuse midline glioma characterized by the presence of histone H3 K27M mutation. [1]

Diffuse midline glioma, H3 K27M-mutants most frequently harbor alterations in H3F3A, TP53, PIK3CA, HIST1H3B, and PPM1D [2].

Most Commonly Altered Genes in Diffuse Midline Glioma, H3 K27M-Mutant

H3F3A Mutation, H3F3A K28M, TP53 Mutation, TP53 Missense, and TP53 c.217-c.1178 Missense are the most common alterations in diffuse midline glioma, H3 K27M-mutant [2].

Top Alterations in Diffuse Midline Glioma, H3 K27M-Mutant

Clinical Trials

View Clinical Trials for Diffuse Midline Glioma, H3 K27M-Mutant

There are 17 clinical trials for diffuse midline glioma, H3 K27M-mutant, of which 16 are open and 1 is completed or closed. Of the trials that contain diffuse midline glioma, H3 K27M-mutant as an inclusion criterion, 11 are phase 1 (11 open), 2 are phase 1/phase 2 (1 open), and 4 are phase 2 (4 open).

H3F3A, EGFR, and HIST1H3C are the most frequent gene inclusion criteria for diffuse midline glioma, H3 K27M-mutant clinical trials [3].

Trials Investigating Diffuse Midline Glioma, H3 K27M-Mutant by Gene and Recruiting Status

Radiation therapy, pvs-ripo, and atezolizumab are the most common interventions in diffuse midline glioma, H3 K27M-mutant clinical trials.

Drugs Being Investigated in Diffuse Midline Glioma, H3 K27M-Mutant Trials by Recruiting Status

Significant Genes in Diffuse Midline Glioma, H3 K27M-Mutant

APC +

APC is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains APC status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK6 +

CDK6 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

CTDNEP1 +

CTDNEP1 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains CTDNEP1 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

CTNNB1 +

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

DDX3X +

DDX3X is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR +

EGFR is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 +

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 2 (1 open) [3].

GLI2 +

GLI2 is altered in 4.17% of diffuse midline glioma, H3 K27M-mutant patients [2].

GLI2 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains GLI2 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A +

H3F3A is altered in 72.55% of diffuse midline glioma, H3 K27M-mutant patients [2].

H3F3A is an inclusion eligibility criterion in 7 clinical trials for diffuse midline glioma, H3 K27M-mutant, of which 7 are open and 0 are closed. Of the trials that contain H3F3A status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

HIST1H3C +

HIST1H3C is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains HIST1H3C status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH1 +

IDH1 is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 +

IDH2 is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

KDM6A +

KDM6A is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2C +

KMT2C is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains KMT2C status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2D +

KMT2D is altered in 3.92% of diffuse midline glioma, H3 K27M-mutant patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP1B +

LRP1B is altered in 4.26% of diffuse midline glioma, H3 K27M-mutant patients [2].

LRP1B is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 +

MDM4 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC +

MYC is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYC status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCL +

MYCL is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYCL status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN +

MYCN is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

OTX2 +

OTX2 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains OTX2 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D +

PPM1D is altered in 16.0% of diffuse midline glioma, H3 K27M-mutant patients [2].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

PTCH1 +

PTCH1 is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN +

PTEN is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

PVT1 +

PVT1 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains PVT1 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

RELA +

RELA is altered in 2.08% of diffuse midline glioma, H3 K27M-mutant patients [2].

RELA is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains RELA status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

SHH +

SHH is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains SHH status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 +

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

SMO +

SMO is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains SMO status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

SNCAIP +

SNCAIP is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains SNCAIP status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

SUFU +

SUFU is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains SUFU status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

TERT +

TERT is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains TERT status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 +

TP53 is altered in 43.14% of diffuse midline glioma, H3 K27M-mutant patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

YAP1 +

YAP1 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains YAP1 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

ZMYM3 +

ZMYM3 is an inclusion eligibility criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains ZMYM3 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [3].

Disease Details

Parent(s)

Malignant Glioma

Children

Diffuse Intrinsic Pontine Glioma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Diffuse Midline Glioma, H3 K27M-Mutant

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Diffuse Midline Glioma, H3 K27M-Mutant

Disease Details

References

About

Molecular Medicine

Content Types